A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
Italy- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Back to Italy22 clinical trials in Cefalu', Italy. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in ItalyStudi-Clinici.it(opens in a new tab)
Italy
Italy
Italy
Italy
Italy
Italy
Italy
Italy
Italy
Italy
Italy
ItalyThe busiest research cities in the country
What the registry says about research in the country
Comprehensive studies focusing on various forms of Multiple Sclerosis (MS), including relapsing-remitting and primary progressive types. Research aims to evaluate new therapeutic approaches and long-term treatment effectiveness.
Multiple ongoing trials examining innovative treatments like ABP 692, ocrelizumab, and LY3541860.
Groundbreaking research investigating treatments for Early Alzheimer's Disease and mild cognitive impairment. Studies focus on evaluating new compounds and their effects on disease progression.
Clinical trials examining promising compounds like BAN2401 and GSK4527226 for early intervention.
Diverse studies examining various neurological conditions, including Myasthenia Gravis and MOG antibody-associated disease. Research focuses on innovative treatment approaches.
Investigations include rozanolixizumab for MOGAD and telitacicept for generalized Myasthenia Gravis.
Tell us about your condition – we search every trial in Europe and connect you with the right site.